Moderna, Inc. (MRNA)

In January 2025, Moderna's shares fell sharply due to projected revenue decline and cost-cutting measures. In February 2025, the stock closed up despite a loss per share, but revenue decreased due to declining COVID-19 vaccine sales. In March 2025, Moderna's stock increased after CEO stock acquisitions and a patent dispute victory. In May 2025, the stock jumped due to successful clinical trials, followed by a correction in June; Q1 results showed continued losses and revenue decline, with regulatory approval for the flu/COVID combination vaccine pushed to 2026. In June 2025, Moderna received FDA approval for its RSV vaccine, mRESVIA, and announced positive Phase 3 results for its seasonal influenza vaccine. In July 2025, the FDA granted full approval for Moderna's COVID-19 Vaccine, Spikevax, for children, but the company cancelled plans to build a manufacturing plant in Japan.

Demand for Moderna's respiratory products, especially COVID-19 vaccines, is transitioning to a seasonal commercial market. The majority of product sales for respiratory vaccines are expected in the second half of the year, impacting revenue streams and commercial strategies.

Moderna, Inc., a biotechnology company in Cambridge, Massachusetts, focuses on mRNA therapeutics and vaccines. It operates in the Healthcare sector, specifically Biotechnology and Pharmaceutical industries, using its mRNA platform to instruct cells to produce proteins that prevent or fight disease. Moderna's commercial products include the Moderna COVID-19 vaccine (Spikevax) and mRESVIA (RSV vaccine). The company has a pipeline of mRNA-based therapeutics and vaccines targeting infectious diseases, immuno-oncology, rare genetic disorders, and autoimmune diseases, with 44 mRNA development programs as of early 2022, including 25 in clinical trials.

Moderna's headquarters and primary operations, including manufacturing sites, are in Cambridge, Massachusetts. It has expanded globally through partnerships and subsidiaries. In Europe, Moderna has a commercial presence in Italy, France, Germany, Spain, Switzerland, the United Kingdom, Belgium, Denmark, the Netherlands, Norway, Poland, and Sweden. In the Asia-Pacific region, it has subsidiaries in Japan, South Korea, and Australia, with a commercial network including Malaysia, Taiwan, Singapore, and Hong Kong. Plans for a manufacturing facility in Kenya were paused, and plans to build an mRNA manufacturing plant in Japan were cancelled in July 2025.

Moderna has a strong reputation as an employer, ranking as the number one large employer in BioSpace's 2025 Best Places to Work report for the fourth consecutive year and consistently ranking in Science and Science Careers' Top Employers Survey for ten years. However, mRNA vaccines face distrust and safety concerns compared to traditional vaccines, amplified by social media misinformation. Discussions revolve around safety, trust, and effectiveness, with negative sentiments increasing in recent years. Moderna has also faced scrutiny over executive stock sales.

Moderna's ownership includes institutional, retail, and individual investors. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Baillie Gifford & Co, Fmr Llc, State Street Corp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, VFINX - Vanguard 500 Index Fund Investor Shares, Geode Capital Management, Llc, Morgan Stanley, and Theleme Partners LLP. Institutional investors hold over 73% of the company's shares, and insiders also hold a notable percentage.